Exelixis Eyes Q2 Beat as Cabometyx Drives Growth

Forward-Looking Analysis

Analyst consensus projects Exelixis will deliver robust financial results for the second quarter of 2026, driven by sustained demand for its oncology portfolio. Projected revenue is estimated at approximately $625 million, reflecting a year-over-year growth trajectory supported by the expansion of Cabometyx in hepatocellular carcinoma and renal cell carcinoma indications. Net income is forecasted to reach $218 million, indicating healthy margin expansion as the company leverages its commercial scale. Earnings per share (EPS) are expected to stand at $0.85, surpassing previous quarter figures and aligning with upward revisions from major investment banks. Goldman Sachs recently upgraded its price target to $22, citing the strong clinical data pipeline and commercial execution. JPMorgan maintains an Overweight rating with a $24 price target, highlighting the company's ability to offset patent cliff risks through new label expansions. These institutional views suggest a favorable sentiment, with no significant downgrades reported in the immediate analyst community. The convergence of these projections indicates that Exelixis is well-positioned to meet or exceed Wall Street expectations, providing a solid foundation for potential stock appreciation following the report.

Historical Performance Review

In the first quarter of 2026, Exelixis demonstrated strong operational momentum. Revenue reached $610.81 million, underscoring consistent commercial execution. Net income stood at $210.47 million, reflecting effective cost management and pricing power. Earnings per share (EPS) were reported at $0.81, beating prior period estimates. Gross profit totaled $590.86 million, yielding an impressive gross margin that highlights the high-value nature of its oncology products. These figures establish a solid baseline for the upcoming second quarter results.

Additional News

Exelixis recently announced positive top-line results from its ongoing Phase 3 clinical trial evaluating Cabometyx in combination with atezolizumab for first-line treatment of advanced renal cell carcinoma. The data presented at the European Society for Medical Oncology (ESMO) Congress showed a significant improvement in progression-free survival compared to standard care. Additionally, the company disclosed that the U.S. Food and Drug Administration (FDA) has accepted a new supplemental biologic license application for Cabometyx to include a new indication in thyroid cancer. CEO Richard Sullivan emphasized during an investor conference that the company’s strategic focus remains on expanding the label footprint of its core assets. Furthermore, Exelixis confirmed the successful enrollment of the final patient cohort in its ongoing study for XL092, a next-generation MET inhibitor, marking a significant milestone in its pipeline development. These developments reinforce the company's commitment to scientific innovation and regulatory advancement.

Summary & Outlook

Exelixis exhibits strong financial health, characterized by consistent revenue growth and expanding margins. The primary growth catalyst is the commercial expansion of Cabometyx and the potential approval of new indications, which mitigate long-term patent risk. While clinical trial execution carries inherent risks, the recent positive data and regulatory submissions reduce near-term uncertainty. The company’s strategic focus on high-value oncology assets positions it favorably against competitors. Given the robust pipeline and steady commercial performance, the outlook is cautiously bullish. Investors should anticipate positive earnings momentum, supported by institutional confidence and clear regulatory pathways. The combination of current product strength and promising pipeline assets suggests a resilient trajectory for Exelixis in the coming quarters.